A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and toxicity in 42 patients who underwent HDT with ASCT.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
42
Rituximab infusion on day 1 dose: 375mg/m²
University Hospital
Nantes, France
CR rate after 3 high dose chemotherapy courses
Time frame: safety/efficacy of chemotherapy treatment
CR and PR rate at the end of the study treatment
Time frame: safety/efficacy of treatment30 days after the end of post ASCT aplasia
PFS,EFS and OS
Time frame: safety/efficacy of study treatment
Tolerance of Rituximab combined with chemotherapy
Time frame: safety/efficacy of immunotherapy combined with chemotherapy treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.